{"id":171423,"date":"2026-09-21T23:08:14","date_gmt":"2026-09-21T23:08:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/171423\/"},"modified":"2026-09-21T23:08:14","modified_gmt":"2026-09-21T23:08:14","slug":"stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/171423\/","title":{"rendered":"StockWatch: Novo&#8217;s 2030 Strategy Underwhelms Investors at Capital Markets Day"},"content":{"rendered":"<p>        <a href=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2026\/09\/NovoNordisk-Bagsvaerd-HQ-JPEG-drone-1280px-contact-us.jpg\" data-caption=\"Novo Nordisk&#039;s corporate headquarters in Bagsvaerd,&#010;Denmark. Novo has laid out a longterm strategy that underwhelmed investors of the Danish metabolic biotech giant, resulting in an 8% loss for the stock on Monday.  [Novo Nordisk]\" rel=\"nofollow noopener\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" width=\"696\" height=\"427\" class=\"entry-thumb td-modal-image\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/09\/NovoNordisk-Bagsvaerd-HQ-JPEG-drone-1280px-contact-us-696x427.jpg\"   alt=\"\" title=\"NovoNordisk-Bagsvaerd-HQ-JPEG-drone-1280px-contact-us\"\/><\/a>Novo Nordisk&#8217;s corporate headquarters in Bagsvaerd,<br \/>\nDenmark. Novo has laid out a longterm strategy that underwhelmed investors of the Danish metabolic biotech giant, resulting in an 8% loss for the stock on Monday.  [Novo Nordisk]<\/p>\n<p>A week after loosening up its branding to \u201cNovo,\u201d Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO) laid out a strategy for 2030 that underwhelmed investors of the Danish metabolic biotech giant.<\/p>\n<p>Addressing investors at its 2026 Capital Markets Day, Novo CEO Maziar (Mike) Doustdar and other company executives laid out a series of initiatives aimed at restoring its edge in metabolic and other drugs by growing and diversifying its pipeline, as well as driving sustainable growth, and delivering attractive returns.<\/p>\n<p>To that end, Doustdar and colleagues said Novo planned to launch \u201cmore than five multi-blockbusters\u201d or drugs with multiple billions of dollars in sales every year through 2030. Those five are expected to emerge from more than five Phase III programs in obesity and diabetes, and another 5+ Phase III programs in other therapeutic areas.<\/p>\n<p>Doustdar also committed Novo to generating more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035, a figure that includes current pipeline assets. Novo plans to combine internal pipeline growth with external growth through merger-and-acquisition (M&amp;A) activity.<\/p>\n<p>\u201cNovo is targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors,\u201d cautioned Evan David Seigerman, a managing director and head of healthcare research at BMO Capital Markets, in a research note.<\/p>\n<p>Seigerman cited a consensus of analysts that estimates a 3.53% compound annual growth rate (CAGR) for Novo, vs. ~3.65% CAGR for its pharma peers. However, he added, \u201cNovo\u2019s outlined growth expectation appears already priced in to [Wall] Street estimates, reading negatively to shares.\u201d<\/p>\n<p>Key to Novo\u2019s new strategy, Doustdar said, was planning for the eventual loss of U.S. patent exclusivity in 2032 for its best-selling drug semaglutide, the glucagon-like peptide-1 (GLP-1) drug marketed as Ozempic\u00ae for type 2 diabetes in adults and as Wegovy\u00ae for obesity\/weight control\u2014what the CEO called \u201cthe elephant in the room.\u201d<\/p>\n<p>\u201cWe plan to come on the other side of the LOE [loss of exclusivity] as a bigger company than we are today and a much more diversified version of it,\u201d Doustdar said. \u201cWe created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us. We need to be ready for that.\u201d<\/p>\n<p>\u2018Not seeing concrete news\u2019<\/p>\n<p>Those and other priorities laid out at the annual capital markets event failed to reassure Novo investors. The company\u2019s primary shares on Nasdaq Copenhagen slumped nearly 8% this morning from DKK 281.55 ($43.19) to an even DKK 260.00 ($39.89). On the New York Stock Exchange, Novo\u2019s American depositary receipts (ADRs) also tumbled 8% from $43.24 to $39.81.<\/p>\n<p>\u201cInvestors are selling the shares because they are not seeing concrete news that could drive the stock higher,\u201d Per Hansen, investment economist at Nordnet, wrote in a research note, as reported by Bloomberg News.<\/p>\n<p>Speaking on CNBC, Hansen elaborated: \u201cInvestors hoped for a project \u2018miracle\u2019 that could turn the momentum around short term. For obvious reasons that miracle does not exist.\u201d<\/p>\n<p>Markus Manns, a portfolio manager \u200bat Union Investment, told Reuters he was less than impressed by Novo\u2019s projections of 2030 sales and a \u201cbroadly stable\u201d operating margin.<\/p>\n<p>\u201cThey (also) did not say much in terms of \u200chow to \u2060tackle the semaglutide patent expiration in 2032,\u201d said Manns, who added that he thought Novo made a credible case for pursuing next-generation obesity drugs and a broader early-stage pipeline.<\/p>\n<p>In its presentation, Novo detailed the drugs it expects to launch each year through 2030\u2014starting with next year, when the company plans to launch once-weekly CagriSema (cagrilintide and semaglutide), a diabetes and obesity drug which combines the long-acting amylin receptor agonist with the GLP-1 receptor agonist. Cagrilintide and a high-dose version of CagriSema are scheduled for a 2028 launch, while 2029 is expected to deliver launches of high-dose cagrilintide; zenagamtide, a multi-receptor peptide agonist targeting GLP-1, amylin, and calcitonin receptors; an oral form of zenagamtide; and a next-generation GLP-1.<\/p>\n<p>In 2030, Novo\u2019s launch calendar includes a monthly-dose or \u201cQM\u201d GLP-1; a thermostable GLP-1; an oral high-yield GLP-1; Amylin 355 and an oral version, both long-acting amylin analogues; an oral ACSL5 inhibitor LX9851, co-developed with Lexicon Pharmaceuticals; and UBT251, a long-acting synthetic peptide triple agonist that targets GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors and is being co-developed by Novo with Chinese-owned United Biotechnology.<\/p>\n<p>Monday\u2019s selloff of Novo shares and ADRs lowered the company\u2019s one-year stock performance to a 33% decline year over year on Nasdaq Copenhagen and a 35% drop on the NYSE.<\/p>\n<p>By contrast, shares of Novo\u2019s archrival in obesity and diabetes drug development, Eli Lilly (NYSE: LLY), have soared 55% year over year, from $754.95 on September 22, 2025 (September 21 was a Sunday) to $1,164.66, up 1% from Friday\u2019s close of $1,152.93.<\/p>\n<p>While Bagsvaerd, Denmark-based Novo Nordisk was first to market with a GLP-1 drug when Ozempic became commercially available in February 2018, Indianapolis-based Lilly has grown to a majority share of GLP-1 drug sales\u2014though Lilly\u2019s blockbuster tirzepatide, marketed for diabetes as Mounjaro\u00ae and for obesity as Zepbound\u00ae, are dual-agonists of GLP-1 and GIP receptors.<\/p>\n<p>2-to-1 sales edge<\/p>\n<p>Lilly has grown its GLP-1-based drug sales so far this year to a nearly 2-to-1 edge over Novo. The two Lilly drugs have racked up a combined $27.6 billion-plus in revenue\u2014$18.605 billion for Mounjaro, $9.088 billion for Zepbound\u2014accounting for about 65% of Lilly\u2019s total $42.773 billion in revenue between January and June 2026.<\/p>\n<p>By contrast, Novo\u2019s GLP-1 blockbusters have racked up a combined DKK 102.393 billion ($15.715 billion) in sales in the first half of 2026, accounting for about 69% of the company\u2019s total DKK 148.551 billion ($22.798 billion) in adjusted sales.<\/p>\n<p>Ozempic garnered DKK 59.2 billion ($9.085 billion), down 8% from DKK 64.52 billion ($9.902 billion) year over year, while its injectable Wegovy generated sales of DKK 37.719 billion ($5.789 billion), up 2% from DKK 36.888 billion ($5.661 billion) in Q1-Q2 2025. The company also made DKK 5.474 billion ($840 million) in sales from oral Wegovy, which reached the U.S. market on January 5.<\/p>\n<p>Lilly\u2019s competing oral obesity drug Foundayo\u00ae (orforglipron), a small molecule GLP-1 receptor agonist, generated $98 million in its first quarter on the market, having won FDA approval on April 1.<\/p>\n<p>Doustdar took Novo\u2019s helm in August 2025, intent on regaining the company\u2019s competitive edge in GLP-1 based obesity and diabetes drugs after Lilly\u2019s sales successes with Mounjaro and Zepbound. A year ago this month, Doustdar led the company\u2019s deepest personnel reduction, which <a href=\"https:\/\/www.genengnews.com\/topics\/translational-medicine\/stockwatch-analysts-see-pain-and-necessity-in-novo-nordisks-9000-layoffs\/\" target=\"_blank\" rel=\"noopener nofollow\">eliminated about 9,000 jobs<\/a>.<\/p>\n<p>In addition to those initial layoffs, Novo said Monday that 4,000 additional staffers exited the company, resulting in 13,000 fewer employees than a year ago, bringing the company\u2019s workforce down to approximately 66,000 employees.<\/p>\n<p>Novo said its restructuring generated more than DKK 10 billion ($1.534 billion) in savings that is being allocated to its R&amp;D operations, commercial growth brands, and manufacturing right-sizing efforts. The company also said it reduced its spending on external services by ~30% year-to-date and has renegotiated agreements with suppliers to squeeze out further savings.<\/p>\n<p>Flurry of announcements<\/p>\n<p>In the week leading to and including Monday\u2019s Capital Markets Day, Novo issued a flurry of announcements\u2014including a poke at Lilly by highlighting during the event positive topline results from the Phase III REIMAGINE 5 trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06534411\" target=\"_blank\" rel=\"noopener nofollow\">NCT06534411<\/a>) and REDEFINE 9 trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06388187\" target=\"_blank\" rel=\"noopener nofollow\">NCT06388187<\/a>) assessing CagriSema, which the company trumpeted as \u201cNovo\u2019s next innovation in weight management and type 2 diabetes.\u201d<\/p>\n<p>In REIMAGINE 5, CagriSema 1.0 mg\/1.0 mg showed superiority to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1% for the Lilly drug. CagriSema also confirmed a non-inferior reduction in HbA1c of 1.71% vs. 1.67% for tirzepatide.<\/p>\n<p>In REDEFINE 9, CagriSema 1.0 mg\/1.0 mg showed a dramatic weight reduction of 21.0% vs. 2.0% for placebo, meeting that study\u2019s primary superiority endpoint. CagriSema also showed greater improvements than placebo across prespecified endpoints that included systolic blood pressure, waist-to-height ratio, and fasting lipid profile.<\/p>\n<p>The rush of announcements started September 14 with a rebrand that shortened the company\u2019s name in marketing materials to \u201cNovo,\u201d accompanies by an updated Apis bull logo, while keeping \u201cNovo Nordisk\u201d as its legal name. \u00a0The company also unveiled a new slogan, \u201cLasting Health Starts Now.\u201d<\/p>\n<p>\u201cThe rebrand is designed to be more memorable and relevant to the way people engage with their health today,\u201d Novo stated in a press release announcing the rebrand. \u201cIt also reflects the company\u2019s ambition to bring breakthrough science closer to people\u2019s daily lives and to strengthen recognition and trust as Novo reaches more people in more ways.\u201d<\/p>\n<p>Anthropic, Orbis partnerships<\/p>\n<p>Novo also announced a collaboration of undisclosed value with Anthropic (draft Form S-1 Registration Statement filed June 1) to bolster artificial intelligence (AI)-based drug development. Novo agreed to use Anthropic models and Claude Science to advance scientific reasoning for R&amp;D and agentic software engineering, with the aim of helping Novo discover and develop new treatments faster.<\/p>\n<p><a href=\"https:\/\/www.genengnews.com\/topics\/artificial-intelligence\/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications\/\" target=\"_blank\" rel=\"noopener nofollow\">Launched in June<\/a>, Claude Science is an AI workbench for scientists that consolidates fragmented research tools, including more than 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer.<\/p>\n<p>On Thursday, privately held Orbis Medicines announced an up-to-$1.4 billion strategic collaboration and license agreement with Novo, bringing together the two Danish-based drug developers to discover and develop an undisclosed number of next-generation oral macrocycle therapeutics for unspecified cardiometabolic diseases.<\/p>\n<p>The potential $1.4 billion reflects an upfront payment and payments tied to achieving development and commercial milestone payments. Copenhagen-based Orbis will also gain a strategic investment of undisclosed amount from Novo, and potentially gain tiered royalties on future product sales.<\/p>\n<p>Novo plans to apply Orbis\u2019 lab-in-the-loop nGen platform which integrates generative AI and high-throughput synthesis, using a multi-parameter optimization (MPO) engine to design nCycles with desirable properties\u2014detailed in a <a href=\"https:\/\/www.nature.com\/articles\/s41589-023-01496-y\" target=\"_blank\" rel=\"noopener nofollow\">2023 Nature Chemical Biology paper<\/a> as including target biding and other key properties for oral availability, such as proteolytic stability, membrane permeability and metabolic stability. Orbis says it continuously improves its nCycles through one of the industry\u2019s largest experimental macrocycle datasets, which the company generates in real time via its platform.<\/p>\n<p>Novo\u2019s interest in macrocycles appears to reflect a desire to overcome limitations associated with traditional oral peptide treatments, such as low digestive absorption. The 2023 paper showed Orbis\u2019 macrocycles to have an oral bioavailability of up to 18% in rats: \u201cThis method for generating orally available peptides is general and provides a promising push toward unlocking the full potential of peptides as therapeutics.\u201d<\/p>\n<p>Other announcements:<\/p>\n<p>Frehemgo\u00ae (denecmig) won a positive opinion from the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use recommending approval for the next-generation factor VIIIa mimetic bispecific antibody to treat hemophilia A, with or without inhibitors, in adults and children.<br \/>\nDenecimig generated positive results in the Phase III FRONTIER5 trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05878938\" target=\"_blank\" rel=\"noopener nofollow\">NCT05878938<\/a>), showing that a direct switch to a subcutaneous denecimig pen injector from a vial and syringe injection system for a current Hemophilia A treatment emicizumab, marketed by Genentech as Hemlibra\u00ae, was well tolerated with no unforeseen safety concerns in adolescents and adults with hemophilia A.<br \/>\nSogroya\u00ae (somapacitan) also won a positive CHMP opinion for the human growth hormone analogue as a once-weekly treatment for children with idiopathic short stature (ISS) with persistent growth disturbance. The drug won FDA approval in 2020.<\/p>\n<p class=\"trimmed\">\u00a0<\/p>\n<p>Leaders &amp; Laggards<\/p>\n<p>BlossomHill Therapeutics (Nasdaq: BLSM) shares jumped 21% over two days, from $22.17 Tuesday to $26.82 Thursday, after the small molecule cancer drug developer announced positive updated data from the ongoing Phase I\/II SOLARA trial (<a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06706076&amp;data=05%7C02%7C%7C910e8a28d5b44d79e93508df16b4a643%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639254640331799833%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=66HNYXwsL%2FkUCzbwX5byzEvK10dAyp4Qb73DsSj1lSQ%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener nofollow\">NCT06706076<\/a>) assessing BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S. In patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 showed a 45% objective response rate (18 of 40 patients) and an 88% disease control rate (35 of 40 patients). At the time of efficacy follow-up, 25 of 40 patients (63%) remained on treatment with a median follow-up of 6.9 months. BlossomHill presented the data at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul.<br \/>\nXenon Pharmaceuticals (Nasdaq: XENE) shares tumbled 31% from $57.35 to $39.75 Friday, after the neuroscience-focused drug developer acknowledged that it voluntarily paused enrollment of new patients in two Phase III programs encompassing five trials assessing its potent KV7 potassium channel opener azetukalner\u2014the three-program X-NOVA program in major depressive disorder (MDD), and the two-trial X-CEED program in bipolar depression\u2014following an analysis of neuropsychiatric adverse events. \u201cIn a very small number of patients, we have seen an adverse event captured under the broad preferred term of psychosis,\u201d Xenon chief medical officer Christopher Kenney, MD, told analysts on a conference call. Those events had not previously been seen in the Phase II X\u2011NOVA trial in MDD (<a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05376150&amp;data=05%7C02%7C%7C910e8a28d5b44d79e93508df16b4a643%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639254640331924574%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=U1cOhoMva78qYqG5FM%2F4Wz9R%2BKtAqeW0qY9GE4ZsvQ8%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener nofollow\">NCT05376150<\/a>), Xenon said, adding that the observed events, their rate of occurrence, and their severity, were consistent with the known safety and tolerability profile of azetukalner and its mechanism.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk&#8217;s corporate headquarters in Bagsvaerd, Denmark. Novo has laid out a longterm strategy that underwhelmed investors of&hellip;\n","protected":false},"author":2,"featured_media":171424,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[79050,15786,15659,276,2960,79049,79048,17678,20640,694,1339,38,272,357,79051,1858,70627],"class_list":["post-171423","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-and-therapeutics","tag-diabetes","tag-diagnosis","tag-eli-lilly","tag-eli-lilly-and-company","tag-endocrine-diseases","tag-gen-edge","tag-industry-news","tag-lilly","tag-medicine","tag-metabolic-disorders","tag-news","tag-novo-nordisk","tag-obesity","tag-systemic-conditions","tag-topics","tag-translational-medicine"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117311550823706664","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=171423"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171423\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/171424"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=171423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=171423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=171423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}